Creative Medical Technology Holdings, Inc. (CELZ) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCELZ / S&P -29.61% / 15.20% |
LoseCELZ / S&P -50.00% / 15.00% |
LoseCELZ / S&P -34.91% / 50.40% |
| 2026-Q11/3 |
WinCELZ / S&P 5.10% / -4.33% |
LoseCELZ / S&P -78.57% / 11.30% |
LoseCELZ / S&P -43.83% / 27.70% |
| 2025-Q41/3 |
LoseCELZ / S&P -41.14% / 2.65% |
LoseCELZ / S&P -45.45% / 9.00% |
WinCELZ / S&P 15.11% / 13.40% |
| 2025-Q31/3 |
WinCELZ / S&P 25.66% / 8.12% |
LoseCELZ / S&P -45.45% / 4.61% |
LoseCELZ / S&P CELZ unavailable / 13.45% |
| 2025-Q21/3 |
WinCELZ / S&P 22.12% / 10.94% |
LoseCELZ / S&P -64.71% / 4.83% |
LoseCELZ / S&P CELZ unavailable / 10.63% |
| 2025-Q11/3 |
LoseCELZ / S&P -6.06% / -4.27% |
WinCELZ / S&P 55.56% / 4.98% |
LoseCELZ / S&P CELZ unavailable / 10.57% |
| 2024-Q41/3 |
LoseCELZ / S&P -25.48% / 2.41% |
WinCELZ / S&P 22.22% / 5.25% |
LoseCELZ / S&P CELZ unavailable / 6.15% |
| 2024-Q30/3 |
LoseCELZ / S&P -19.48% / 5.89% |
LoseCELZ / S&P -55.28% / 5.89% |
LoseCELZ / S&P CELZ unavailable / 6.11% |
| 2024-Q20/3 |
LoseCELZ / S&P -26.10% / 4.28% |
LoseCELZ / S&P -76.90% / 5.38% |
LoseCELZ / S&P CELZ unavailable / 5.12% |
| 2024-Q11/3 |
WinCELZ / S&P 13.02% / 10.56% |
LoseCELZ / S&P -87.77% / 5.71% |
LoseCELZ / S&P CELZ unavailable / 5.59% |
| 2023-Q40/3 |
LoseCELZ / S&P -6.30% / 11.69% |
LoseCELZ / S&P -89.84% / 6.81% |
LoseCELZ / S&P CELZ unavailable / 7.78% |
| 2023-Q31/3 |
WinCELZ / S&P 6.15% / -3.27% |
LoseCELZ / S&P -82.14% / 7.52% |
LoseCELZ / S&P CELZ unavailable / -5.03% |
| 2023-Q20/3 |
LoseCELZ / S&P -7.30% / 8.74% |
LoseCELZ / S&P -20.65% / 9.50% |
LoseCELZ / S&P CELZ unavailable / -8.57% |
| 2023-Q11/3 |
WinCELZ / S&P 31.20% / 7.50% |
LoseCELZ / S&P -28.37% / 10.77% |
LoseCELZ / S&P CELZ unavailable / -15.69% |
| 2022-Q40/3 |
LoseCELZ / S&P -13.39% / 7.56% |
LoseCELZ / S&P 0.96% / 11.88% |
LoseCELZ / S&P -119.52% / -17.99% |
| 2022-Q31/3 |
LoseCELZ / S&P -41.33% / -4.88% |
WinCELZ / S&P 267.34% / 13.47% |
LoseCELZ / S&P -91.55% / -1.41% |
| 2022-Q20/3 |
LoseCELZ / S&P -80.77% / -16.10% |
LoseCELZ / S&P -11.24% / 13.71% |
LoseCELZ / S&P -90.15% / 11.04% |
| 2022-Q11/3 |
WinCELZ / S&P 76.47% / -4.60% |
LoseCELZ / S&P -16.05% / 15.97% |
LoseCELZ / S&P -87.91% / 42.23% |
| 2021-Q40/3 |
LoseCELZ / S&P -70.53% / 11.03% |
LoseCELZ / S&P -46.65% / 15.00% |
LoseCELZ / S&P -107.89% / 96.40% |
| 2021-Q30/3 |
LoseCELZ / S&P -57.14% / 0.58% |
LoseCELZ / S&P -73.70% / 10.77% |
LoseCELZ / S&P CELZ unavailable / 69.42% |
| 2021-Q20/3 |
LoseCELZ / S&P 5.42% / 8.55% |
LoseCELZ / S&P -15.11% / 6.58% |
LoseCELZ / S&P CELZ unavailable / 51.81% |
| 2021-Q11/3 |
WinCELZ / S&P 19.42% / 6.17% |
LoseCELZ / S&P -21.94% / -1.06% |
LoseCELZ / S&P CELZ unavailable / 7.39% |
| 2020-Q42/3 |
WinCELZ / S&P 858.62% / 12.15% |
WinCELZ / S&P -0.60% / -3.72% |
LoseCELZ / S&P CELZ unavailable / -33.42% |
| 2020-Q30/3 |
LoseCELZ / S&P -38.30% / 8.93% |
LoseCELZ / S&P -37.32% / -2.04% |
LoseCELZ / S&P CELZ unavailable / -27.10% |
| 2020-Q20/3 |
LoseCELZ / S&P 4.44% / 20.54% |
LoseCELZ / S&P -44.65% / -0.46% |
LoseCELZ / S&P CELZ unavailable / -27.11% |
| 2020-Q10/3 |
LoseCELZ / S&P -90.00% / -19.60% |
LoseCELZ / S&P -5.31% / 3.47% |
LoseCELZ / S&P CELZ unavailable / -14.75% |
| 2019-Q41/3 |
LoseCELZ / S&P -62.50% / 9.07% |
WinCELZ / S&P 33.04% / 5.36% |
LoseCELZ / S&P CELZ unavailable / 2.99% |
| 2019-Q31/3 |
LoseCELZ / S&P -79.49% / 1.70% |
WinCELZ / S&P 217.74% / 5.02% |
LoseCELZ / S&P CELZ unavailable / 0.21% |
| 2019-Q21/3 |
LoseCELZ / S&P -61.39% / 4.30% |
WinCELZ / S&P 1058.33% / 6.64% |
LoseCELZ / S&P CELZ unavailable / 8.65% |
| 2019-Q11/3 |
LoseCELZ / S&P 2.02% / 13.65% |
WinCELZ / S&P 1050.00% / 8.12% |
LoseCELZ / S&P CELZ unavailable / 14.29% |
| 2018-Q41/3 |
LoseCELZ / S&P -57.69% / -13.52% |
WinCELZ / S&P 2491.67% / 9.05% |
LoseCELZ / S&P CELZ unavailable / 18.23% |
| 2018-Q30/3 |
LoseCELZ / S&P -57.45% / 7.71% |
LoseCELZ / S&P CELZ unavailable / 10.21% |
LoseCELZ / S&P CELZ unavailable / 19.06% |
| 2018-Q21/3 |
WinCELZ / S&P 467.01% / 3.43% |
LoseCELZ / S&P CELZ unavailable / 9.03% |
LoseCELZ / S&P CELZ unavailable / 14.46% |
| 2018-Q10/3 |
LoseCELZ / S&P -28.15% / -0.76% |
LoseCELZ / S&P CELZ unavailable / 7.68% |
LoseCELZ / S&P CELZ unavailable / 12.46% |
| 2017-Q40/3 |
LoseCELZ / S&P -93.25% / 6.64% |
LoseCELZ / S&P CELZ unavailable / 7.03% |
LoseCELZ / S&P CELZ unavailable / 13.82% |
| 2017-Q30/3 |
LoseCELZ / S&P -55.56% / 4.48% |
LoseCELZ / S&P CELZ unavailable / 5.68% |
LoseCELZ / S&P CELZ unavailable / 17.57% |
| 2017-Q20/3 |
LoseCELZ / S&P -11.76% / 3.09% |
LoseCELZ / S&P CELZ unavailable / 4.83% |
LoseCELZ / S&P CELZ unavailable / 17.74% |
| 2017-Q10/3 |
LoseCELZ / S&P 0.00% / 6.07% |
LoseCELZ / S&P CELZ unavailable / 3.67% |
LoseCELZ / S&P CELZ unavailable / 13.32% |
| 2016-Q40/3 |
LoseCELZ / S&P 0.00% / 3.82% |
LoseCELZ / S&P CELZ unavailable / 2.09% |
LoseCELZ / S&P CELZ unavailable / 7.05% |
| 2016-Q31/3 |
WinCELZ / S&P 54.55% / 3.85% |
LoseCELZ / S&P CELZ unavailable / 0.20% |
LoseCELZ / S&P CELZ unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CELZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -64.15% | 20.78% |
| Annualized return | -64.15% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CELZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.14% | 83.14% |
| Annualized return | -61.37% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CELZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -71.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |